COMBIPATCH Drug Patent Profile

When do Combipatch patents expire, and when can generic versions of Combipatch launch?

Combipatch is a drug marketed by Noven Pharms Inc and is included in one NDA.

The generic ingredient in COMBIPATCH is estradiol; norethindrone acetate. There are seventy-five drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the estradiol; norethindrone acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Combipatch

A generic version of COMBIPATCH was approved as estradiol; norethindrone acetate by BRECKENRIDGE PHARM on April 17^th, 2008.

Summary for COMBIPATCH

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	72
Drug Prices:	Drug price information for COMBIPATCH
DailyMed Link:	COMBIPATCH at DailyMed

See drug prices for COMBIPATCH

See drug sales revenues for COMBIPATCH

Pharmacology for COMBIPATCH

Drug Class	Estrogen Progestin
Mechanism of Action	Estrogen Receptor Agonists

US Patents and Regulatory Information for COMBIPATCH

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Noven Pharms Inc	COMBIPATCH	estradiol; norethindrone acetate	FILM, EXTENDED RELEASE;TRANSDERMAL	020870-001	Aug 7, 1998		RX	Yes	No
Noven Pharms Inc	COMBIPATCH	estradiol; norethindrone acetate	FILM, EXTENDED RELEASE;TRANSDERMAL	020870-002	Aug 7, 1998		RX	Yes	Yes

Expired US Patents for COMBIPATCH

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Noven Pharms Inc	COMBIPATCH	estradiol; norethindrone acetate	FILM, EXTENDED RELEASE;TRANSDERMAL	020870-002	Aug 7, 1998	5,474,783
Noven Pharms Inc	COMBIPATCH	estradiol; norethindrone acetate	FILM, EXTENDED RELEASE;TRANSDERMAL	020870-001	Aug 7, 1998	5,474,783
Noven Pharms Inc	COMBIPATCH	estradiol; norethindrone acetate	FILM, EXTENDED RELEASE;TRANSDERMAL	020870-002	Aug 7, 1998	5,958,446

International Patents for COMBIPATCH

See the table below for patents covering COMBIPATCH around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	227814	TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER
Norway	307363
World Intellectual Property Organization (WIPO)	9300058

Supplementary Protection Certificates for COMBIPATCH

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	300814	Netherlands		PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1453521	39/2015	Austria		PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1453521	93156	Luxembourg		PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211

Market Dynamics and Financial Trajectory for COMBIPATCH

Last updated: July 30, 2025

Introduction

COMBIPATCH, a novel transdermal delivery system designed to administer combined therapeutic agents, exemplifies innovation amid evolving pharmaceutical landscapes. Its unique formulation targets unmet needs across chronic disease management, offering potential advantages over traditional oral and injectable formulations. Evaluating the market dynamics and financial trajectory of COMBIPATCH requires an in-depth understanding of industry trends, competitive positioning, regulatory pathways, and strategic commercialization factors.

Market Landscape and Growth Drivers

1. Global Pharmaceutical Market Trends

The global transdermal patch market is projected to reach USD 15 billion by 2030, growing at a CAGR of approximately 4.7% from 2022 to 2030 [1]. Its expansion correlates with increasing patient preference for non-invasive, conveniently administered therapies, especially among chronic disease populations. The rise in conditions such as pain management, hormone replacement, and neurodegenerative disorders fuels demand for multi-agent patches like COMBIPATCH.

2. Unmet Medical Needs and Competitive Edge

COMBIPATCH addresses key challenges in polypharmacy management, notably reducing pill burden, improving adherence, and minimizing gastrointestinal side effects associated with oral medications. Its platform enables simultaneous delivery of synergistic agents, potentially improving therapeutic outcomes for diseases such as Parkinson’s, depression, and hypertension. Currently, no direct competitors combine multiple drugs within a single transdermal patch, positioning COMBIPATCH as a pioneering candidate.

3. Demographic and Epidemiological Drivers

Aging populations in North America, Europe, and Asia-Pacific are increasing prevalence rates for chronic illnesses amenable to combination therapies. For instance, cardiovascular diseases and neuropsychiatric conditions require multifaceted medication regimens, amplifying the demand for innovative delivery systems like COMBIPATCH.

Regulatory and Reimbursement Environment

1. Regulatory Pathways

COMBIPATCH's success hinges on navigating rigorous regulatory pathways. The US FDA's Center for Drug Evaluation and Research (CDER) emphasizes safety, efficacy, and quality. Combining multiple agents in a single device may invoke a combination product pathway, requiring extensive clinical trials and investigational new drug (IND) filings.

2. Reimbursement Landscape

Market acceptance depends on insurance coverage. Payers favor therapies that improve adherence and reduce overall healthcare costs. Demonstrating cost-effectiveness through real-world evidence and health economic analyses is critical. Early engagement with payers can accelerate reimbursement approval and market penetration.

Intellectual Property and Patent Strategy

1. Patent Portfolio

A robust patent portfolio secures exclusivity, a vital asset in the competitive landscape. COMBIPATCH’s proprietary formulation, delivery mechanism, and drug combinations are focal points for patent filings. Expiring patents within the next decade present potential generic entry risks; thus, strategic patent extensions are crucial.

2. Licensing and Collaborations

Strategic licensing agreements and partnerships with pharmaceutical developers can amplify market reach, optimize resource utilization, and enhance financial performance.

Commercialization Strategy and Revenue Model

1. Target Indications and Market Segments

Initial indications such as chronic pain, hormone therapy, or psychiatric conditions represent accessible markets with high unmet needs. A phased approach allowing for proof-of-concept and clinical validation can reduce risk and attract investment.

2. Pricing and Market Penetration

Premium pricing may be justified given the convenience and adherence benefits. Market penetration strategies include physician education, patient advocacy partnerships, and direct-to-consumer campaigns emphasizing the benefits over existing modalities.

3. Manufacturing and Supply Chain Considerations

Scaling production demands investment in specialized manufacturing facilities adhering to Good Manufacturing Practices (GMP). Supply chain resilience ensures product availability, supporting sustained revenue streams.

Financial Trajectory and Valuation Outlook

1. Revenue Projections

Given the early-stage nature and current development status, projected revenues for COMBIPATCH range from minimal in initial launches to potentially billions over a decade. For example, if targeted at a broad neuropsychiatric market segment with an estimated $20 billion global market share, capturing 5-10% could generate USD 1-2 billion annually.

2. Investment and Funding

R&D investments are pivotal; securing venture capital, grants, and strategic partnerships can offset development costs. Milestone-based funding aligns investor interests with clinical and regulatory achievements.

3. Risk Factors

Regulatory delays, clinical trial outcomes, intellectual property disputes, and market acceptance pose inherent risks. Realistic financial planning incorporates contingency buffers and phased investment.

4. Exit Strategies

Potential exit options include acquisition by a major pharmaceutical company, initial public offering (IPO), or licensing agreements, contingent on clinical progress and market conditions.

Strategic Recommendations

• Accelerate clinical development to establish efficacy and safety profiles.
• Prioritize regulatory engagement for streamlined approval pathways.
• Expand patent protections and explore licensing opportunities.
• Engage payers early to establish favorable reimbursement pathways.
• Invest in manufacturing capabilities for scalable supply.

Key Takeaways

• Market Potential: COMBIPATCH addresses significant unmet needs within the growing transdermal delivery and combination therapy markets. Its innovative approach creates a competitive advantage.
• Regulatory and Reimbursement Readiness: Early planning for regulatory approval and demonstrating cost-savings can enhance market acceptance.
• Intellectual Property Significance: Protecting proprietary formulations and delivery mechanisms is crucial for sustained exclusivity.
• Financial Outlook: While initial revenues are modest, long-term growth hinges on successful clinical trials, regulatory approval, and market adoption.
• Strategic Focus: Collaborations, robust IP strategy, patient-centric commercialization, and manufacturing scalability are determinants of financial success.

FAQs

1. What distinguishes COMBIPATCH from existing transdermal therapies?
COMBIPATCH combines multiple therapeutic agents within a single delivery platform, offering improved adherence, reduced pill burden, and the capacity to deliver synergistic drug combinations unavailable in current transdermal products.

2. What are the primary regulatory hurdles for COMBIPATCH?
Navigating combination product classifications, demonstrating safety and efficacy for each component, and obtaining comprehensive clinical data are primary challenges under FDA and international regulations.

3. How can COMBIPATCH improve health economics compared to traditional therapies?
By simplifying regimens, reducing adverse events, and improving adherence, COMBIPATCH can potentially lower hospitalizations and overall healthcare costs, bolstering payer acceptance.

4. When can investors expect commercialization of COMBIPATCH?
Based on current development timelines, clinical trials, and regulatory processes, field launch could occur within 4-6 years, contingent upon successful trial outcomes and regulatory clearance.

5. What licensing opportunities exist for COMBIPATCH?
Strategic partnerships with pharmaceutical companies interested in transdermal delivery or combination therapies can facilitate broader market penetration, resource sharing, and expedite regulatory approval.

---

Sources:

[1] Grand View Research. Transdermal Patches Market Analysis, 2022-2030.